Images are still loading please cancel your preview and try again shortly.

Accessibility tools

Healthcare and Life Sciences

Leading life science organisations and emerging healthcare companies trust Linklaters lawyers to help navigate them through the myriad of challenges to achieve their goals in a highly regulated and rapidly changing healthcare industry

Linklaters has a long history of advising clients in the healthcare sector. We have developed strong working relationships and a deep understanding of our client’s business environment, enabling us to provide solutions orientated advice when managing and implementing highly complex, cross-border transactions and other business critical scenarios.

Our clients are many of the world’s biggest players in the healthcare sector, ranging from pharmaceutical, biotech, and medical equipment manufacturing organisations, through to healthcare services groups, banks, private equity houses and sovereign wealth funds.

Our healthcare expertise

Our clients draw on our expertise in all areas, including corporate finance, mergers and acquisitions, product commercialisation, supply chains, IP, tax, regulation, litigation, and antitrust. More specifically:

  • We can support our clients as they expand their businesses in both established and growth markets, whether through M&A, joint ventures, distribution agreements or by other means, including through the evolution into a digital world;
  • We have one of the world’s preeminent antitrust practices with a dedicated sector focus. We have unparalleled expertise and continued involvement in the highest profile and most complex antitrust cases at national, EU and global level, ranging from strategic M&A mandates to cutting-edge behavioural and regulatory assignments;
  • Our IP practice works with a number of healthcare companies protecting, enforcing and defending their IP rights. Our IP team includes highly experienced litigators and advisers on non-contentious commercial issues and agreements; and
  • We know the healthcare regulatory issues and have excellent relationships with specialist regulatory healthcare lawyers in key jurisdictions. We work closely with the firm’s other sector teams, especially our Consumer and Technology sectors, to anticipate and address industry convergence trends.

Our healthcare teams are based in many of the key business hubs across the Americas, Asia and Europe including Belgium, China, Germany, France, Singapore, the United Kingdom and the United States.

Related insights

Scroll to explore our related content

medicine pills

After Lundbeck: Is the “pay for delay” debate over?

Close X
close up of test tubes

Digital Health

Close X
hand pressing screen

The MDR is here Regulatory changes and their impact on liability

Close X
scientist looking down microscope

The European Commission struck down on pharma pricing. Shook Aspen - and the whole forest?

Close X
Monitor

Covid-19: Supplying vital medical equipment in uncertain times and managing regulatory, contractual and reputational risk

Close X
molecules

Covid-19: Impact on EU Healthcare Regulation

Close X
   

Recent healthcare and life sciences transactions

Gavi

Gavi on the establishment of the COVAX facility for the funding and allocation of Covid vaccines globally, including on its participation principles, its supplier volume commitment arrangements and other related arrangements and the interrelation between these and agreements with CEPI, BMGF and sovereign state participants.

Read our press release

Unilabs

Apax Partners on the €5bn sale of Unilabs, a leading pan-European provider of laboratory and imaging diagnostics services, to A.P. Moller Holding. 

Read our press release

Bayer AG

Bayer AG in connection with its acquisition of UK-based biotech KaNDy Therapeutics Ltd, to expand its drug development pipeline in women’s healthcare.

Read our press release

Takeda

Takeda on the disposal of its haemostasis product TachoSil to Corza Health Inc for €350m.

Read our press release

Takeda

Takeda in relation to several ground-breaking matters, including its £46bn recommended offer for Shire plc, the largest ever outbound M&A deal by a Japanese company; and waiver from commitment to divest the development compound SHP-647, the first-ever European Commission waiver of a pipeline merger divestment commitment.

Neuraxpharm

Apax Partners on its auction sale process of Neuraxpharm, a leading European speciality pharmaceutical company focused on the treatment of central nervous system disorders. The largest European pharma deal in 2020.

Read our press release

Bayer AG

Bayer AG on the US$7.6bn sale of its animal health business to Elanco Animal Health to create a leading global animal health company. 

 

QIAGEN N.V.

QIAGEN N.V. on the aborted business combination agreement and the friendly takeover by the US technology group Thermo Fisher Scientific worth €10.4bn.

Cerba Health

Partners Group on the €3bn sale of its interests in Cerba Healthcare to EQT Private Equity. 

Read our press release

Nestlé

Nestlé advising on the £7.8bn sale of its Skin Health division and related global supply and distribution arrangements.

Nestlé Health Science

Nestlé Health Science on the drafting and negotiation of complex licence and supply agreements with Valbiotis, for the purposes of the development and global commercialisation of an innovative, patented dietary supplement, for diabetic and pre-diabetic patients.

Carlyle and PAI Partners

Carlyle and PAI Partners on their acquisition of Theramex, the leading global specialty pharmaceuticals company focused on women’s health, from CVC Capital Partners. Theramex serves more than six million women in 57 countries across EMEA, APAC and South America.

Read our press release

Johnson & Johnson

Johnson & Johnson on several transactions, including its acquisition of Abbott Medical Optics (US$ 4.3 billion), Synthes (US$ 21.3 billion), Pfizer Consumer Healthcare (US$ 16.6 billion), and Guidant (US$ 21.1 billion), the sale of Codman Neurosurgery (US$ 1 billion), Ortho-Clinical Diagnostics Inc (US$ 4.15billion) and divestment of Cordis Corporation (US$ 2billion).

McKesson

McKesson on its strategy to streamline its business in Europe, including the sale of McKesson Europe businesses in France, Italy, Ireland, Portugal, Belgium, and Slovenia to the PHOENIX group; the sale of its UK business, including Lloyds Pharmacy, to AURELIUS; and the German wholesale joint venture with Walgreens Boots Alliance.

Bupa

Bupa on its partnership with a virtual consultation app start-up, including on its investment in the start-up and its technology arrangements for development and distribution of customisations designed to give the provider a competitive advantage in a number of jurisdictions in Asia, Europe and the Middle East, including on the privacy, IT, commercial and medical device issues arising.

ViiV Healthcare

ViiV Healthcare on their settlement with Gilead Sciences, resolving litigation relating to Biktarvy and ViiV’s dolutegravir patents and entry into a patent licence agreement.

Genomics England

Genomics England on a range of commercial, technology, public law, competition/state aid, privacy and corporate governance issues relating to its achievement of its public interest and commercial objectives. We also advised them in respect of their agreement with Illumina, who provided genome sequencing services to Genomics England, and key data privacy and technology issues arising out of such contracts.

Key healthcare and life sciences sector contacts

x Find a Lawyer